Asset Management One Co. Ltd. Buys 6,266 Shares of Stryker Corporation $SYK

Key Points

• Asset Management One Co. Ltd. has increased its ownership in Stryker Corporation by 4.4%, now holding 149,071 shares valued at approximately $58.98 million.
• Insider Ronda E. Stryker sold 200,000 shares for $75.29 million, representing a 5.84% decrease in her position, while company insiders collectively own 5.90% of the stock.
• Stryker's stock is currently rated as a Moderate Buy by analysts, with a consensus target price of $432.24 and recent quarterly earnings surpassing expectations.

Asset Management One Co. Ltd. raised its holdings in Stryker Corporation (NYSE:SYK - Free Report) by 4.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 149,071 shares of the medical technology company's stock after purchasing an additional 6,266 shares during the quarter. Asset Management One Co. Ltd.'s holdings in Stryker were worth $58,977,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently bought and sold shares of SYK. Mid American Wealth Advisory Group Inc. bought a new position in Stryker in the 2nd quarter valued at $26,000. Sachetta LLC grew its stake in Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company's stock valued at $29,000 after purchasing an additional 27 shares during the period. Goodman Advisory Group LLC bought a new position in Stryker in the 1st quarter valued at $32,000. Ridgewood Investments LLC grew its stake in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company's stock valued at $36,000 after purchasing an additional 30 shares during the period. Finally, Ransom Advisory Ltd bought a new position in Stryker in the 1st quarter valued at $37,000. Institutional investors own 77.09% of the company's stock.

Insider Activity

In other Stryker news, insider Viju Menon sold 500 shares of the firm's stock in a transaction dated Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the sale, the insider owned 12,511 shares of the company's stock, valued at $4,886,921.71. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on SYK shares. Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a research note on Saturday, October 18th. Evercore ISI cut their price target on Stryker from $418.00 to $410.00 and set an "outperform" rating for the company in a research note on Tuesday, October 7th. Needham & Company LLC increased their price target on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Rothschild Redb upgraded Stryker to a "hold" rating in a research note on Thursday, September 18th. Finally, Weiss Ratings reiterated a "buy (b-)" rating on shares of Stryker in a research note on Wednesday, October 8th. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $432.24.

Stryker Stock Performance

Shares of SYK opened at $383.40 on Friday. The stock's 50-day simple moving average is $379.84 and its 200 day simple moving average is $379.42. The stock has a market capitalization of $146.58 billion, a price-to-earnings ratio of 50.78, a price-to-earnings-growth ratio of 2.80 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.06 and a current ratio of 1.78. Stryker Corporation has a 52-week low of $329.16 and a 52-week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.07 by $0.06. The business had revenue of $6.02 billion for the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm's quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Research analysts forecast that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker's dividend payout ratio is 44.50%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.